#USA #Laser Technology #Prague #BTL #EXOLASE ONE®

Introduction

BTL, a renowned leader in advanced medical and aesthetic technologies, has marked a pivotal moment in its history with the establishment of a dedicated laser division and the introduction of its flagship laser system, EXOLASE ONE®. This innovative device is celebrated as the first application of fused erbium laser technology in the medical field, setting a new standard for facial rejuvenation treatments.

The Cutting-Edge Technology

Manufactured at BTL’s high-tech facility in Europe, EXOLASE ONE® stands out by merging multiple erbium laser wavelengths into a single light beam. This allows for the simultaneous targeting of the same spot on the skin, resulting in an unprecedented interaction between the laser and tissues. BTL's groundbreaking approach aims to overcome traditional limitations of existing facial rejuvenation lasers regarding clinical effectiveness, treatment speed, and patient comfort.

Dr. Reha Yavuzer, a pioneering clinical researcher who tested EXOLASE ONE®, noted, "This technology consolidates what typically requires multiple ablative and non-ablative systems, transforming the treatment into an exceptionally simple procedure that revitalizes the entire face in under ten minutes, delivering superior outcomes for our patients."

Impact on the Aesthetic Industry

The advent of EXOLASE ONE® marks a significant advance in the aesthetics sector, promising to revolutionize approaching laser treatments for various skin concerns. With its simplified process, this device has the potential to enhance patient satisfaction and streamline practices in aesthetic medicine.

Tomas Schwarz, CEO of BTL, expressed his enthusiasm: "This is a historic moment for BTL. From the outset, we understood that only a truly revolutionary technology could position us as a leading figure in laser treatments." Feedback from pioneering clinical centers worldwide has indicated that EXOLASE ONE® embodies the breakthrough the industry has been awaiting.

Future Launch Plans

After a successful early access program with key opinion leaders, EXOLASE ONE® is set for a larger global launch in 2027, initially targeting the aesthetic medicine and dermatology sectors. This new laser division becomes BTL's sixth primary division, enhancing its existing operations in aesthetics, mental wellness, rehabilitation, cardiology, and robotics.

About BTL

Founded in 1993, BTL has evolved to become one of the world’s foremost manufacturers of medical and aesthetic equipment. With over 5,000 employees across more than 90 countries, BTL has made significant strides in non-invasive solutions for body contouring, skin tightening, facial rejuvenation, mental health, rehabilitation, and cardiology. Among its pioneering brands are EMSCULPT NEO®, EMFACE®, EMSELLA®, and EXOMIND®. For more information about BTL and its portfolio of medical innovations, visit BTL Aesthetics.

As the industry gears up for the launch of EXOLASE ONE®, all eyes will be on BTL as it continues to push the boundaries of technology in medical aesthetics, promising a brighter and more effective future for treatments around the globe.